Myelo Therapeutics GmbH - News
News

June 26th, 2020: Myelo Therapeutics Closes Financing Round and Gains Strong Backing of Eckert & Ziegler Group. Myelo Therapeutics GmbH - News

May 11th, 2020: Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million for Development of Myelo001 as Treatment for Acute Radiation Syndrome. Myelo Therapeutics GmbH - News

Nov 4th, 2019: New data confirming Myelo001 efficacy in Acute Radiation Syndrome presented at 65th annual meeting of the Radiation Research Society.

July 24th, 2019: EMA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

Dec 4th, 2018: Positive Data on Efficacy of Myelo001 in treating Acute Radiation Syndrome published in Blood.

Sep 25th, 2018: FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome.

March 1st, 2018: Myelo Therapeutics has been selected as a finalist of the Lyfebulb-Helsinn Innovation Summit Award in Oncology..

Nov 8th, 2017: Interview on progress of Myelo001 development program and Myelo Therapeutics experience with Elsevier’s “The Hive” incubator program.

Oct 4th, 2017: Myelo Therapeutics’ Phase II study of Myelo001 in Chemotherapy-induced Neutropenia is fully recruited.

June 20th, 2017: Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round.

Jan 16th, 2017: New data published in Blood confirms that the chemo-protective effect of Myelo001 is specific to healthy tissue.

Jan 13th, 2017: Myelo Therapeutics is selected as one of four companies worldwide to participate in Elsevier's incubator project.

previous news »